OncoPharm

Topics covered:

1. Trilaciclib's approval to minimize bone marrow suppression

2. Cemiplimab's approval for mNSLC with high PD-L1 expression

3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma

4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer

5. More of the same with lenvatinib + pembrolizumab in mRCC

Happy Birthday to a drug that ushered in its own era! We discuss its history and development and just a little bit about its benefit, role, and a few clinical pearls.

Discussing the latest TKI approval, umbralisib, and its familiar toxicity profile. Also, a few final words on a new CAR-T product and a cemiplimab expanded approval.

In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.

With the recent FDA-approval of nivolumab + cabozantinib for metastatic renal cell carcinoma (mRCC, we review Checkmate-9ER results and how they compare to other combination treatments in mRCC. We then end by discussion preliminary recommendations on vaccinating patients with cancer agains COVID-19.

Checkmate-9ER abstract: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-cabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-first-results-from-the-randomized-phase-iii-checkmate-9er-trial

Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis.

DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413

Our landmarks of OncoPharm series returns to discuss JBR10, adjuvant cisplatin/vinorelbine in NSCLC.

JBR10: https://www.nejm.org/doi/pdf/10.1056/NEJMoa043623

JBR10 Update: https://pubmed.ncbi.nlm.nih.gov/19933915/

LACE meta-analysis: https://pubmed.ncbi.nlm.nih.gov/18506026/

The 1st episode of 2021 covers 5 FDA updates from December 2020

-Pralsetinib for RET-mutated medullary thyroid cancer

-The new HER2-targeting margetuximab

-Selinexor and the Boston study

-Relugolix, an oral GnRH antagonist

-Adjuvant osimertinib approved (ADAURA)

Our Foundations of Oncopharm series returns to discuss the history and use of trastuzumab.

Highlighting some of the bright spots, oncopharm & otherwise, for our Holiday episode. Best new drug? Best study? Best movie to take my mind off of a pandemic? Enjoy this episode with a glass of Holiday Cheer.